[Ip-health] MSF Statement for the WHO Executive Board

[Mark Patterson]

>One
pragmatic and effective way of doing this is to provide countries with
examples or models of intellectual property legislation that will allow
them to develop TRIPS compliant laws * all the while making maximum use
of the safeguards of the TRIPS agreement to ensure that pharmaceutical
patents do not hamper access to medicines.=20

Have such models been produced?  Alternatively, is there a consensus as to =
which country's current laws best accomplish these goals?